In this article
Novo Nordisk
is looking for deals more than ever before, the CEO of the Danish drugmaker said in an interview with CNBC on Wednesday.
“If our ambition is to help hundreds of millions of patients out there, then we need not just the best, but the broadest pipeline in the world,” said Novo Nordisk CEO Mike Doustdar. “So let’s go and see who else basically has assets that are complementary to what we have. And we are quite active with those [business development] talks and acquisitions, and you’ll see more of those as well going forward.”
Novo created the market for GLP-1 weight loss drugs with its weekly shots Ozempic and Wegovy. More recently, the company has faced concerns from analysts about whether Novo’s pipeline is robust enough for it to remain a leader in the increasingly competitive obesity drug space.
